<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69375</article-id><article-id pub-id-type="doi">10.7554/eLife.69375</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralisation of P.1 Brazilian variant</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-236799"><name><surname>Parry</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236800"><name><surname>Tut</surname><given-names>Gokhan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236803"><name><surname>Bruton</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236801"><name><surname>Faustini</surname><given-names>Sian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236802"><name><surname>Stephens</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236804"><name><surname>Saunders</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236805"><name><surname>Bentley</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236806"><name><surname>Hilyard</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236807"><name><surname>Brown</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236808"><name><surname>Amirthalingam</surname><given-names>Gayatri</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236809"><name><surname>Charlton</surname><given-names>Sue</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236810"><name><surname>Leung</surname><given-names>Stephanie</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8880-2977</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236811"><name><surname>Chiplin</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236812"><name><surname>Coombes</surname><given-names>Naomi S</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236813"><name><surname>Bewley</surname><given-names>Kevin R</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236814"><name><surname>Penn</surname><given-names>Elizabeth J</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236815"><name><surname>Rowe</surname><given-names>Cathy</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236816"><name><surname>Otter</surname><given-names>Ashley</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236817"><name><surname>Watts</surname><given-names>Rosie</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236818"><name><surname>D'Arcangelo</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236819"><name><surname>Hallis</surname><given-names>Bassam</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236820"><name><surname>Makin</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-236821"><name><surname>Richter</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192178"><name><surname>Zuo</surname><given-names>Jianmin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-148122"><name><surname>Moss</surname><given-names>Paul</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6895-1967</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution>University of Birmingham</institution>, <addr-line><named-content content-type="city">Birmingham</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution>Quinton and Harborne PCN</institution>, <addr-line><named-content content-type="city">Ridgacre House Surgery, Quinton</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution>Vaccine Taskforce</institution>, <addr-line><named-content content-type="city">Department for Business, Energy and Industrial Strategy,  London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><institution>National infection Service</institution>, <addr-line><named-content content-type="city">Public Health England, Colindale, London NW9 5EQ</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution>National infection Service</institution>, <addr-line><named-content content-type="city">Public Health England,  Porton Down, Salisbury, SP4 OJG</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><institution content-type="dept">Research</institution>, <institution>National Infection Service</institution>, <addr-line><named-content content-type="city">Salisbury</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff7"><institution>Oxford Immunotec Ltd</institution>, <addr-line><named-content content-type="city">Abingdon, OX14 4SE</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-41027"><name><surname>Van der Meer</surname><given-names>Jos W</given-names></name><role>Reviewing editor</role><aff><institution>Radboud University Medical Centre</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>p.moss@bham.ac.uk</email> (PM);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>09</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e69375</elocation-id><history><date date-type="received"><day>13</day><month>04</month><year>2021</year></date><date date-type="accepted"><day>24</day><month>09</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Parry et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Parry et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-69375-v1.pdf"/><abstract><p>Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials. We determined the serological and cellular response to spike protein in 100 people aged 80-96 years at 2 weeks after second vaccination with the Pfizer BNT162b2 mRNA vaccine. Antibody responses were seen in every donor with high titres in 98%. Spike-specific cellular immune responses were detectable in only 63% and correlated with humoral response. Previous SARS-CoV-2 infection substantially increased antibody responses after one vaccine and antibody and cellular responses remained 28-fold and 3-fold higher respectively after dual vaccination. Post-vaccine sera mediated strong neutralisation of live Victoria infection and although neutralisation titres were reduced 14-fold against the P.1 variant first discovered in Brazil they remained largely effective. These data demonstrate that the mRNA vaccine platform delivers strong humoral immunity in people up to 96 years of age and retains broad efficacy against the P.1 Variant of Concern.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>National Core Studies</institution></institution-wrap></funding-source><award-id>Immunity programme</award-id><principal-award-recipient><name><surname>Parry</surname><given-names>Helen</given-names></name><name><surname>Tut</surname><given-names>Gokhan</given-names></name><name><surname>Bruton</surname><given-names>Rachel</given-names></name><name><surname>Faustini</surname><given-names>Sian</given-names></name><name><surname>Stephens</surname><given-names>Christine</given-names></name><name><surname>Moss</surname><given-names>Paul</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>UK Coronavirus Immunology Consortium</institution></institution-wrap></funding-source><award-id>UKRI/DHSC</award-id><principal-award-recipient><name><surname>Parry</surname><given-names>Helen</given-names></name><name><surname>Tut</surname><given-names>Gokhan</given-names></name><name><surname>Bruton</surname><given-names>Rachel</given-names></name><name><surname>Faustini</surname><given-names>Sian</given-names></name><name><surname>Stephens</surname><given-names>Christine</given-names></name><name><surname>Moss</surname><given-names>Paul</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Andrew Makin, is affiliated with Oxford Immunotec Ltd. The author has no financial interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Informed consent, and consent to publish, was obtained. The study was approved by UPH IRAS ethics 282164, Health Research Authority UK.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All primary data are available at https://doi.org/10.5281/zenodo.4740081</p></sec><supplementary-material><ext-link xlink:href="elife-69375-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>